Gainesville, FL, United States of America

Arun Srivastava

This inventor holds 26 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Gene Therapy. Top assignees: University of Florida Research Foundation Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arun Srivastava. Retrieved from https://idiyas.com/inventor/arun-srivastava

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 22)

% Patents Active = 84.6

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 3.9

ph-index = 10

Forward Citations = 378(Granted Patents)

Company Filing History:

25 out of 3,050

University of Florida Research Foundation Inc.

patents

1 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Gene Therapy

AAV Vectors

Transduction Efficiency

Liver Cancer

Recombinant Vectors

Capsid Modification

Hairpin mRNA

Therapeutic Methods

Tyrosine-Modified

Oncology

Vector Compositions

Protein Translation

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570699 - CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER (2026-03-10),

2. 12569573 - ENHANCED TRANSDUCTION OF AAV VECTORS ENCODING MICRORNAS (2026-03-10),

3. 12358954 - Capsid-modified rAAV vector compositions and methods therefor (2025-07-15),

4. 12065467 - High-transduction-efficiency rAAV vectors, compositions, and methods of use (2024-08-20),

5. 11434260 - High-transduction-efficiency rAAV vectors, compositions, and methods of use (2022-09-06),

6. 11266748 - Recombinant adeno-associated virus vectors to target medullary thyroid carcinoma (2022-03-08),

7. 11124544 - AAV vectors with high transduction efficiency and uses thereof for gene therapy (2021-09-21),

8. 11034974 - Hairpin MRNA elements and methods for the regulation of protein translation (2021-06-15),

9. 10934327 - Capsid-modified, RAAV3 vector compositions and uses in gene therapy of human liver cancer (2021-03-02),

10. 10927150 - Recombinant AAV1, AAV5, and AAV6 capsid mutants and uses thereof (2021-02-23),

11. 10900053 - Genome-modified recombinant adeno-associated virus vectors (2021-01-26),

12. 10815279 - Capsid-modified rAAV vector compositions and methods therefor (2020-10-27),

13. 10723768 - Capsid modified rAAV vectors and methods of use (2020-07-28),

14. 10426844 - Capsid-mutated rAAV vectors and methods of use (2019-10-01),

15. 10308957 - rAAV vectors and methods for transduction of photoreceptors and RPE cells (2019-06-04),

Title: Innovations in Gene Therapy: The Work of Arun Srivastava

Introduction

Arun Srivastava is a prominent inventor located in Gainesville, FL. With an impressive portfolio of 23 patents, he has made significant contributions to the field of gene therapy, especially in the development of advanced vectors for gene delivery. His pioneering work has the potential to transform medical treatments and enhance therapeutic efficacy.

Latest Patents

One of Arun Srivastava's notable inventions includes the development of high-transduction-efficiency rAAV (recombinant adeno-associated virus) vectors. This patent provides AAV capsid proteins modified to enhance the transduction efficiency of a variety of cells, tissues, and organs. The invention offers rAAV virions containing these capsid proteins, along with nucleic acid molecules and rAAV vectors encoding the modified proteins. The enhancements realized in this invention showcase a marked improvement when compared to traditional wild-type rAAV vectors and virions, making it a significant advancement in gene therapy technologies.

Career Highlights

Arun Srivastava currently works at the University of Florida Research Foundation, Incorporated, where his research focuses on gene therapy and vector development. His expertise has positioned him as a key figure in innovative biomedical research, earning him recognition among his peers and within the scientific community.

Collaborations

Throughout his career, Arun Srivastava has collaborated with esteemed colleagues such as Mavis Agbandje-McKenna and Li Zhong. These collaborations have enriched his research efforts, combining expertise to tackle complex challenges in gene therapy and vector engineering.

Conclusion

Arun Srivastava's contributions to the field of gene therapy, particularly through his numerous patents, highlight his role as a leading innovator. By focusing on enhancing the efficiency of gene delivery systems, he continues to pave the way for future advancements in medical treatments. His work at the University of Florida Research Foundation exemplifies how collaboration and innovation can drive significant progress in the realm of health science.

Profile summary based on public USPTO records.